Biotechnology major Biocon on 13 September 2013 inked a pact with CytoSorbents Corporation, under which the Bangalore-based firm will have the exclusive commercialization rights for CytoSorb, a novel therapy for the treatment of sepsis, in India and some emerging markets.
The partnership with CytoSorbents will enable Biotechnology to address the huge unmet need of sepsis management in India and emerging markets. CytoSorb is a first-in-class therapy that can provide an effective solution to physicians to treat critically ill patients suffering from sepsis.
CytoSorbents expects sales of CytoSorb to benefit from Biocon's strong regional sales and distribution network across India.
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.